EUVIMEDEUVIMED entdecken
Leitlinie

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4

Joshua Reuss iD, Nofisat Ismaila iD, Deborah B Doroshow iD, Jill Feldman iD, Gary R MacVicar iD, Vanita Noronha iD, Andreas Saltos iD, Susan C Scott iD, Eric K Singhi, Jennifer Marie Suga, Lyudmila Bazhenova iD

Journal of Clinical Oncology · 29.10.2026

DOI: 10.1200/jco-26-02597 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, online erschienen am 29.10.2026. Verfasst von Joshua Reuss und 10 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown University, Washington, DC, US.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website .

Autor:innen und Institutionen

  • Georgetown University, Washington, DC, US.
  • American Society of Clinical Oncology (ASCO), Alexandria, VA, US.
  • Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY.
  • EGFR Resisters patient advocacy group, Deerfield, IL, US.
  • Illinois CancerCare, Peoria, IL, US.
  • Tata Memorial Centre, India.

ORCID-Profile: Joshua Reuss, Nofisat Ismaila, Deborah B Doroshow, Jill Feldman, Gary R MacVicar, Vanita Noronha, Andreas Saltos, Susan C Scott, Lyudmila Bazhenova

Zitieren

APA

Reuss, J., Ismaila, N., Doroshow, D. B., Feldman, J., MacVicar, G. R., Noronha, V., Saltos, A., Scott, S. C., Singhi, E. K., Suga, J. M., & Bazhenova, L. (2026). Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-02597

Vancouver

Reuss J, Ismaila N, Doroshow DB, Feldman J, MacVicar GR, Noronha V, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-02597

BibTeX
@article{Reuss2026,
  author = {Reuss, Joshua and Ismaila, Nofisat and Doroshow, Deborah B and Feldman, Jill and MacVicar, Gary R and Noronha, Vanita and Saltos, Andreas and Scott, Susan C and Singhi, Eric K and Suga, Jennifer Marie and Bazhenova, Lyudmila},
  title = {Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-02597}
}
Kostenlos starten →